vs
Side-by-side financial comparison of Amgen (AMGN) and Gilead Sciences (GILD). Click either name above to swap in a different company.
Amgen is the larger business by last-quarter revenue ($9.9B vs $7.9B, roughly 1.2× Gilead Sciences). Gilead Sciences runs the higher net margin — 27.5% vs 13.5%, a 14.0% gap on every dollar of revenue. On growth, Amgen posted the faster year-over-year revenue change (8.6% vs 4.7%). Gilead Sciences produced more free cash flow last quarter ($3.1B vs $961.0M). Over the past eight quarters, Amgen's revenue compounded faster (15.1% CAGR vs 8.9%).
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics.
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. Gilead is a member of the Nasdaq-100 and the S&P 100.
AMGN vs GILD — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $9.9B | $7.9B |
| Net Profit | $1.3B | $2.2B |
| Gross Margin | 69.8% | 79.5% |
| Operating Margin | 27.6% | 25.0% |
| Net Margin | 13.5% | 27.5% |
| Revenue YoY | 8.6% | 4.7% |
| Net Profit YoY | 112.6% | 22.4% |
| EPS (diluted) | $2.45 | $1.75 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.9B | $7.9B | ||
| Q3 25 | $9.6B | $7.8B | ||
| Q2 25 | $9.2B | $7.1B | ||
| Q1 25 | $8.1B | $6.7B | ||
| Q4 24 | $9.1B | $7.6B | ||
| Q3 24 | $8.5B | $7.5B | ||
| Q2 24 | $8.4B | $7.0B | ||
| Q1 24 | $7.4B | $6.7B |
| Q4 25 | $1.3B | $2.2B | ||
| Q3 25 | $3.2B | $3.1B | ||
| Q2 25 | $1.4B | $2.0B | ||
| Q1 25 | $1.7B | $1.3B | ||
| Q4 24 | $627.0M | $1.8B | ||
| Q3 24 | $2.8B | $1.3B | ||
| Q2 24 | $746.0M | $1.6B | ||
| Q1 24 | $-113.0M | $-4.2B |
| Q4 25 | 69.8% | 79.5% | ||
| Q3 25 | 67.8% | 79.8% | ||
| Q2 25 | 67.2% | 78.8% | ||
| Q1 25 | 63.6% | 76.9% | ||
| Q4 24 | 65.7% | 79.1% | ||
| Q3 24 | 61.1% | 79.1% | ||
| Q2 24 | 61.4% | 77.8% | ||
| Q1 24 | 57.0% | 76.8% |
| Q4 25 | 27.6% | 25.0% | ||
| Q3 25 | 26.4% | 42.8% | ||
| Q2 25 | 28.9% | 34.9% | ||
| Q1 25 | 14.5% | 33.6% | ||
| Q4 24 | 25.4% | 32.4% | ||
| Q3 24 | 24.1% | 11.8% | ||
| Q2 24 | 22.8% | 38.0% | ||
| Q1 24 | 13.3% | -64.6% |
| Q4 25 | 13.5% | 27.5% | ||
| Q3 25 | 33.7% | 39.3% | ||
| Q2 25 | 15.6% | 27.7% | ||
| Q1 25 | 21.2% | 19.7% | ||
| Q4 24 | 6.9% | 23.6% | ||
| Q3 24 | 33.3% | 16.6% | ||
| Q2 24 | 8.9% | 23.2% | ||
| Q1 24 | -1.5% | -62.4% |
| Q4 25 | $2.45 | $1.75 | ||
| Q3 25 | $5.93 | $2.43 | ||
| Q2 25 | $2.65 | $1.56 | ||
| Q1 25 | $3.20 | $1.04 | ||
| Q4 24 | $1.17 | $1.43 | ||
| Q3 24 | $5.22 | $1.00 | ||
| Q2 24 | $1.38 | $1.29 | ||
| Q1 24 | $-0.21 | $-3.34 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $9.1B | $68.0M |
| Total DebtLower is stronger | $54.6B | $24.9B |
| Stockholders' EquityBook value | $8.7B | $22.7B |
| Total Assets | $90.6B | $59.0B |
| Debt / EquityLower = less leverage | 6.31× | 1.10× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $9.1B | $68.0M | ||
| Q3 25 | $9.4B | $19.0M | ||
| Q2 25 | $8.0B | $69.0M | ||
| Q1 25 | $8.8B | — | ||
| Q4 24 | $12.0B | — | ||
| Q3 24 | $9.0B | — | ||
| Q2 24 | $9.3B | — | ||
| Q1 24 | $9.7B | — |
| Q4 25 | $54.6B | $24.9B | ||
| Q3 25 | $54.6B | $24.9B | ||
| Q2 25 | $56.2B | $24.9B | ||
| Q1 25 | $57.4B | $25.0B | ||
| Q4 24 | $60.1B | $26.7B | ||
| Q3 24 | $60.4B | $23.2B | ||
| Q2 24 | $62.6B | $23.3B | ||
| Q1 24 | $64.0B | $25.2B |
| Q4 25 | $8.7B | $22.7B | ||
| Q3 25 | $9.6B | $21.5B | ||
| Q2 25 | $7.4B | $19.7B | ||
| Q1 25 | $6.2B | $19.2B | ||
| Q4 24 | $5.9B | $19.3B | ||
| Q3 24 | $7.5B | $18.5B | ||
| Q2 24 | $5.9B | $18.3B | ||
| Q1 24 | $5.0B | $17.5B |
| Q4 25 | $90.6B | $59.0B | ||
| Q3 25 | $90.1B | $58.5B | ||
| Q2 25 | $87.9B | $55.7B | ||
| Q1 25 | $89.4B | $56.4B | ||
| Q4 24 | $91.8B | $59.0B | ||
| Q3 24 | $90.9B | $54.5B | ||
| Q2 24 | $90.9B | $53.6B | ||
| Q1 24 | $93.0B | $56.3B |
| Q4 25 | 6.31× | 1.10× | ||
| Q3 25 | 5.67× | 1.16× | ||
| Q2 25 | 7.57× | 1.27× | ||
| Q1 25 | 9.24× | 1.30× | ||
| Q4 24 | 10.23× | 1.38× | ||
| Q3 24 | 8.02× | 1.26× | ||
| Q2 24 | 10.57× | 1.28× | ||
| Q1 24 | 12.75× | 1.44× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $1.6B | $3.3B |
| Free Cash FlowOCF − Capex | $961.0M | $3.1B |
| FCF MarginFCF / Revenue | 9.7% | 39.4% |
| Capex IntensityCapex / Revenue | 6.5% | 2.6% |
| Cash ConversionOCF / Net Profit | 1.20× | 1.52× |
| TTM Free Cash FlowTrailing 4 quarters | $8.1B | $9.5B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.6B | $3.3B | ||
| Q3 25 | $4.7B | $4.1B | ||
| Q2 25 | $2.3B | $827.0M | ||
| Q1 25 | $1.4B | $1.8B | ||
| Q4 24 | $4.8B | $3.0B | ||
| Q3 24 | $3.6B | $4.3B | ||
| Q2 24 | $2.5B | $1.3B | ||
| Q1 24 | $689.0M | $2.2B |
| Q4 25 | $961.0M | $3.1B | ||
| Q3 25 | $4.2B | $4.0B | ||
| Q2 25 | $1.9B | $720.0M | ||
| Q1 25 | $980.0M | $1.7B | ||
| Q4 24 | $4.4B | $2.8B | ||
| Q3 24 | $3.3B | $4.2B | ||
| Q2 24 | $2.2B | $1.2B | ||
| Q1 24 | $459.0M | $2.1B |
| Q4 25 | 9.7% | 39.4% | ||
| Q3 25 | 44.4% | 51.0% | ||
| Q2 25 | 20.8% | 10.2% | ||
| Q1 25 | 12.0% | 24.8% | ||
| Q4 24 | 48.4% | 37.4% | ||
| Q3 24 | 39.0% | 55.2% | ||
| Q2 24 | 26.5% | 17.2% | ||
| Q1 24 | 6.2% | 31.6% |
| Q4 25 | 6.5% | 2.6% | ||
| Q3 25 | 4.6% | 1.9% | ||
| Q2 25 | 4.0% | 1.5% | ||
| Q1 25 | 5.0% | 1.6% | ||
| Q4 24 | 4.1% | 1.9% | ||
| Q3 24 | 3.0% | 1.9% | ||
| Q2 24 | 2.8% | 1.9% | ||
| Q1 24 | 3.1% | 1.6% |
| Q4 25 | 1.20× | 1.52× | ||
| Q3 25 | 1.46× | 1.35× | ||
| Q2 25 | 1.59× | 0.42× | ||
| Q1 25 | 0.80× | 1.34× | ||
| Q4 24 | 7.61× | 1.67× | ||
| Q3 24 | 1.26× | 3.44× | ||
| Q2 24 | 3.30× | 0.82× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMGN
| Products | $9.4B | 95% |
| Xgeva | $291.0M | 3% |
| Vectibix | $163.0M | 2% |
| Aranesp | $115.0M | 1% |
GILD
| Other | $3.4B | 43% |
| HIV Products Biktarvy | $3.3B | 41% |
| HIV Products Odefsey | $239.0M | 3% |
| Liver Disease Products Other Liver Disease | $170.0M | 2% |
| HIV Products Other HIV | $155.0M | 2% |
| Other Products Yescarta | $150.0M | 2% |
| Liver Disease Products Vemlidy | $149.0M | 2% |
| Liver Disease Products Sofosbuvir Velpatasvir | $140.0M | 2% |
| HIV Products Symtuza Revenue Share | $98.0M | 1% |
| Veklury | $80.0M | 1% |
| Cell Therapy Products Tecartus | $32.0M | 0% |
| Royalty Contract And Other | $22.0M | 0% |
